Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 27;6(6):FSO478.
doi: 10.2144/fsoa-2020-0061.

Precision medicine for gastrointestinal cancers: a conference report

Ibrahim Halil Sahin  1
Affiliations

Precision medicine for gastrointestinal cancers: a conference report

Ibrahim Halil Sahin. Future Sci OA. .

Abstract

As cancer management evolves into precision medicine national/international cancer meetings bring novel therapeutic approaches and potentially practice-changing results of clinical studies are presented. This year, the ASCO GI Symposium 2020 had also several updates from ongoing and finalized clinical trials. Although there were no groundbreaking results that impact the daily practice directly, several highly important data from ongoing studies were shared with the audience. In this report, the highlights of the ASCO GI Symposium 2020 are presented with a future perspective.

Keywords: IDH mutations; cholangiocarcinoma; colorectal cancer; gastric cancer; gastrointestinal cancers; hepatocellular carcinoma; immunotherapy; pancreatic cancer; precision medicine.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

References

    1. Guler I, Askan G, Klostergaard J, Sahin IH. Precision medicine for metastatic colorectal cancer: an evolving era. Expert Rev. Gastroentero. L Hepatol. 13(10), 919–931 (2019). - PubMed
    1. Al-Batran S-E, Homann N, Pauligk C. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, Phase II/III trial. Lancet 393(10184), 1948–1957 (2019). - PubMed
    1. van Hagen P, Hulshof M, Van Lanschot J. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Eng. J. Med. 366(22), 2074–2084 (2012). - PubMed
    1. Wainberg ZA, Fuchs CS, Tabernero J. et al. Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1-positive (CPS≥ 10) advanced G/GEJ cancer in the Phase II KEYNOTE-059 (cohort 1) and Phase III KEYNOTE-061 and KEYNOTE-062 studies. Am. Soc. Clin. Oncol. 38, 427 (2020).
    1. Shitara K, Özgüroğlu M, Bang Y-J. et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, Phase III trial. Lancet 392(10142), 123–133 (2018). - PubMed

LinkOut - more resources